Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Enveric iS committed to developing novel treatments to transform the lives of patients living with mental illness. We are pursuing new pathways and targeting impaired neural circuitry with the goal of improving brain health. Our mission is to pioneer new and innovative solutions with the potential to have profound effects on patients and their families, and to deliver life-changing medicines for diseases affecting the brain. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada.
Explore Leadership Team
Investor Relations
Tiberend Strategic Advisors
Daniel Kontoh-Boateng
dboateng@tiberend.com
(862) 213-1398
Jonathan Nugent
jnugent@tiberend.com
(205) 566-3026
Media
Tiberend Strategic Advisors
Casey McDonald
cmcdonald@tiberend.com
(646) 577-8520
Dave Schemelia
dschemelia@tiberend.com
(609) 468-9325
Auditor
Friedman LLP
100 Eagle Rock Avenue, Suite 200
East Hanover, NJ 07936
(973) 929-3500
Transfer Agent
American Stock Transfer and Trust Co.
help@astfinancial.com
(800) 937-5449
U.S. Legal Council
Haynes and Boone, LLP
30 Rockefeller Plaza, 26th Floor
New York, NY 10112
(212) 659-7300